Literature DB >> 16174875

Proglucagon-derived peptides: mechanisms of action and therapeutic potential.

Elaine M Sinclair1, Daniel J Drucker.   

Abstract

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16174875     DOI： 10.1152/physiol.00030.2005

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


  21 in total

1.  Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.

Authors:  Sara Baldassano; Guo-Du Wang; Flavia Mulè; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-10       Impact factor: 4.052

Review 2.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

3.  The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas.

Authors:  J de Heer; J Pedersen; C Orskov; J J Holst
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

4.  Changes in intestinal permeability after Roux-en-Y gastric bypass.

Authors:  Alexandre Lages Savassi-Rocha; Marco Túlio Costa Diniz; Eduardo Garcia Vilela; Maria de Fátima Haueisen Sander Diniz; Soraya Rodrigues de Almeida Sanches; Aloísio Sales da Cunha; Maria de Lourdes de Abreu Ferrari; Henrique Oswaldo da Gama Torres; Bruno Antonio Maciente; Gabriela Santana Ataliba; Paloma Maciel Araújo; Taciana Bretas Guerra; Inara Kellen Fonseca Balbino
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

5.  Paying the price for eating ice cream: is excessive GLP-1 signaling in the brain the culprit?

Authors:  Hans-Rudolf Berthoud
Journal:  Endocrinology       Date:  2008-10       Impact factor: 4.736

Review 6.  Gut microbiota and GLP-1.

Authors:  Amandine Everard; Patrice D Cani
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

7.  A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.

Authors:  Aisling M Lynch; Nupur Pathak; Varun Pathak; Finbarr P M O'Harte; Peter R Flatt; Nigel Irwin; Victor A Gault
Journal:  Diabetologia       Date:  2014-06-25       Impact factor: 10.122

8.  Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.

Authors:  Matthew C Koopmann; David W Nelson; Sangita G Murali; Xiaowen Liu; Mark S Brownfield; Jens J Holst; Denise M Ney
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 May-Jun       Impact factor: 4.016

Review 9.  Glucagon-like peptide 1 based therapy for type 2 diabetes.

Authors:  Bao-Sheng Yu; An-Ru Wang
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

10.  Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome.

Authors:  Matthew C Koopmann; Xiaowen Liu; Christopher J Boehler; Sangita G Murali; Jens J Holst; Denise M Ney
Journal:  JPEN J Parenter Enteral Nutr       Date:  2009-07-30       Impact factor: 4.016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.